- Trial Phase
- Approved / Commercialized
- Time to Market
- Already on the market (FDA-cleared, commercially available)
- Why 4/10
- FemaSeed is already FDA-cleared and marketed, so there is no pending PDUFA or pivotal readout for this product. The next hard catalyst is Category III CPT reimbursement taking effect January 2027 — a commercial/coverage event, not a binary regulatory decision. Per the rubric, an approved marketed drug with no pending regulatory decision scores 3-5; this lands at 4 given the reimbursement catalyst is ~4 months out but is not a make-or-break binary event.
Watch for FemaSeed Cat III reimbursement taking effect January 2027 — this is the clearest commercial catalyst that could drive revenue inflection. However, the massive warrant overhang (up to $90M in potential dilution) and declining core revenue make this a high-risk, binary micro-cap. The next earnings report will show whether the $30M financing is translating into commercial execution.
Price Chart
Executive Summary
FemaSeed is Femasys Inc.'s FDA-cleared, commercially available fertility treatment device — a catheter-based system for intrauterine insemination (IUI) that enables OB/GYNs to perform in-office fertility procedures. Already on the market, FemaSeed faces a slow commercial ramp with the company reporting only ~$757K in total H1 2026 product revenue across its entire portfolio. The key near-term catalyst is Category III CPT reimbursement coverage effective January 2027, which could drive adoption. However, Femasys is a micro-cap ($7M market cap) with heavy dilution from a recent $30M private placement (with warrants for up to $90M more), a 1-for-20 reverse stock split in June 2026, and a cash burn rate that consumed $7.8M in H1 2026. The stock trades near $2.78, down ~67% from its 200-day SMA, with analyst price targets implying ~260% upside but the core business is deteriorating.
How It Works
FemaSeed is a medical device — a catheter system used for intrauterine insemination (IUI), a fertility treatment where specially prepared sperm is placed directly into a woman's uterus to facilitate fertilization. It is designed for use in OB/GYN offices, allowing fertility care to be delivered outside of specialized fertility clinics.
Trial Status
FemaSeed is already FDA-cleared and commercially available in the U.S. The company is executing a commercial launch strategy and has secured Category III CPT reimbursement codes effective January 2027. The product is part of a broader women's health portfolio that also includes FemVue (diagnostic) and FemBloc (non-surgical permanent birth control, currently in FDA-authorized FINALE pivotal trial).
The Two-Sided Case
Upcoming Catalysts
- Category III CPT reimbursement for FemaSeed effective January 2027 — could drive commercial adoption and revenue growth
- FemBloc FINALE pivotal trial enrollment updates and potential readout (separate product, but same company thesis)
- Quarterly earnings reports showing FemaSeed revenue trajectory
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Femasys Inc. PRESS-RELEASE FEMY ·Originating report